Major company in pharma sector Zydus Lifesciences Big news has come from America. The company has received approval for a drug from the US Food and Drug Administration (FDA). clinical trial Approval has been received for. After this news, there is a possibility of a rise in the shares of Zydus in the stock market on the next trading day.
Friday, January 17, 2025 The company's shares closed at Rs 994.15 on BSE. So far this year, Zydus shares have gain of more than 2% Has been registered.
Which medicine has been approved?
Zydus Lifesciences approved by FDA Usnoflast of medicine called Phase II(b) Clinical Trial Approved for. this medicine Amyotrophic lateral sclerosis (ALS) Is being developed for the treatment of.
- Amyotrophic lateral sclerosis (ALS):
It is a serious neurological disease that affects the nerve cells of the brain and spinal cord.- Due to this, control over the muscles is lost.
- There is currently no effective treatment for ALS.
- This medicine from Zydus can be a possible solution for this disease.
After FDA approval, the company will now move to the next phase of testing of this drug, which is an important step in its development.
Stock performance: How much profit in a year?
Shares of Zydus Lifesciences have given excellent returns to investors in the last one year.
- 18 January 2024:
The price of shares was Rs 685.85, which is 1 year low Is. - 9 August 2024:
Shares gained more than 93% Rs 1323.90 Made an all-time high of Rs. - current situation:
This stock is now close to record high 25% down But its strength is still attracting investors.
What are the prospects for investors?
With the approval of FDA, Zydus Lifesciences will get a chance to establish a foothold in a big market like America. This news could not only accelerate the company's future growth, but also send its shares soaring.
- Success in clinical trials If found, the way will be cleared to bring the medicine to the market.
- Success in treating a serious disease like ALS could boost both a company's reputation and revenue.
Comments are closed.